About
Cancer Drug Discovery, Protein Degradation
Areas of Focus
Categories
Small Molecule PharmaceuticalBoston & New England
Team (33)
Adrian Gottschalk
President & CEO
Foghorn Therapeutics
executive
Alena Reva
VP, Total Rewards & People Operations
Foghorn Therapeutics
executive
Alfonso Quintás-Cardama, MD
Chief Medical Officer
Foghorn Therapeutics
executive
Andrew Germain, PHD
VP, Legal
Foghorn Therapeutics
executive
Anna Rivkin, PHD
Chief Business Officer
Foghorn Therapeutics
team_member
Carlos Costa
Chief People Officer
Foghorn Therapeutics
team_member
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
3
As Collaborator
0
Total Enrollment
275
By Phase
PHASE1: 3
By Status
TERMINATED: 2ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT04965753Lead Sponsor
FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors
PHASE1Terminated
55 participants
Started: Aug 17, 2021 · Completed: Dec 4, 2023
NCT04891757Lead Sponsor
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
PHASE1Active, not recruiting
144 participants
Started: Jun 14, 2021 · Completed: Jun 30, 2027
NCT04879017Lead Sponsor
FHD-286 in Subjects With Metastatic Uveal Melanoma
PHASE1Terminated
76 participants
Started: May 11, 2021 · Completed: Nov 30, 2023
Locations (1)
Headquarters
Cambridge, MA, United States
Map
Loading map...